

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 45D1090932	(X3) Date Survey Completed 02/12/2026
Name of Provider or Supplier River City Pain Management, PLLC	Street Address, City, State 9819 Huebner Road, Bldg 1, Suite 113, San Antonio, TX	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	An announced survey of the laboratory was conducted on 02/12/2026. The laboratory was found in substantial compliance with applicable CLIA regulations (42 CFR Part 493, Requirements for Laboratories) for the specialties/subspecialties for which it was surveyed. STANDARD LEVEL DEFICIENCIES were cited.
D5423	<p>ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(2)</p> <p>(b)(2) Each laboratory that modifies an FDA-cleared or approved test system, or introduces a test system not subject to FDA clearance or approval (including methods developed in-house and standardized methods such as text book procedures), or uses a test system in which performance specifications are not provided by the manufacturer must, before reporting patient test results, establish for each test system the performance specifications for the following performance characteristics, as applicable: (b)(2)(i) Accuracy. (b)(2)(ii) Precision. (b)(2)(iii) Analytical sensitivity. (b)(2)(iv) Analytical specificity to include interfering substances. (b)(2)(v) Reportable range of test results for the test system. (b)(2)(vi) Reference intervals (normal values). (b)(2)(vii) Any other performance characteristic required for test performance.</p> <p>This STANDARD is not met as evidenced by: Based on review of laboratory's policies/procedures, test establishment studies, patient test volumes and staff interview, the laboratory failed to document specimen transport stability study as per its own policy prior to start of patient testing for one of one laboratory developed Urine Toxicology Test Panel. Findings included: 1. Review of laboratory's Urine Toxicology Test Panel's establishment study policy "Temperature Stability Study" (document: MediaLab SOP No.22 number 707160.2059 22.TOX; effective: 10/01/2025) revealed: "Sample 5 will be utilized with a temperature logger to document temperature changes during transit and then tested at the lab" 2. Review of laboratory's Urine Toxicology Test Panel's establishment studies, completed and</p>

approved on 10/1/2025, revealed there was no documentation of the laboratory's sample 5 transit temperature study prior to start of patient testing on 10/03/2025. 3. Review of laboratory's submitted test volumes revealed the laboratory performed approximately 152,280 urine toxicology tests from October 2025 through January 2026. 4. In an interview on 02/12/2026 at 1045 hours in the office, the laboratory's Technical Supervisor (as indicated on submitted Form CMS 209) confirmed the findings.

D6086

LABORATORY DIRECTOR RESPONSIBILITIES
CFR(s): 493.1445(e)(3)(ii)

(e)(3)(ii) Verification procedures used are adequate to determine the accuracy, precision, and other pertinent performance characteristics of the method; and

This STANDARD is not met as evidenced by:
Based on review of laboratory's policies/procedures, new test establishment studies, patients test volumes and staff interview the Laboratory Director failed to ensure that establishment studies were complete for one of one test performed by the laboratory in 2025 and 2026, the Urine Toxicology Test Panel. Refer to D5423.

D6115

TECHNICAL SUPERVISOR RESPONSIBILITIES
CFR(s): 493.1451(b)(2)

(b)(2) Verification of the test procedures performed and establishment of the laboratory's test performance characteristics, including the precision and accuracy of each test and test system;

This STANDARD is not met as evidenced by:
Based on review of laboratory's policies/procedures, new test establishment studies, patients test volumes and staff interview the laboratory's Technical Supervisor (as indicated on submitted Form CMS 209) failed to ensure that establishment studies were complete for one of one test performed by the laboratory in 2025 and 2026, the Urine Toxicology Test Panel. Refer to D5423.